Literature DB >> 21179066

Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.

Stefania Zampieri1, Emanuele Buratti, Silvia Dominissini, Anna Lisa Montalvo, Maria Gabriela Pittis, Bruno Bembi, Andrea Dardis.   

Abstract

Glycogen-storage disease type II is an autosomal recessive-inherited disorder due to the deficiency of acid α-glucosidase. A large number of mutations in the acid α-glucosidase gene have been described to date. Among them, ~15% are variations that may affect mRNA splicing process. In this study, we have for the first time comprehensively reviewed the available information on splicing mutations of the acid α-glucosidase gene and we have evaluated their possible impact on the splicing process using different in silico approaches. Out of the 39 different GAA-sequence variations described, an in silico analysis using seven different programs showed that 97% of them are predicted to have an impact on the splicing process. Moreover, this analysis showed a quite good correlation between the impact of the mutation on the splicing process and the clinical phenotype. In addition, we have performed the functional characterization of three novel sequence variants found in Italian patients and still uncharacterized. Using a minigene system, we have confirmed their pathogenic nature. In conclusion, this study has shown that in silico analysis represents a useful tool to select mutations that affect the splicing process of the acid α-glucosidase gene and provides an updated picture of all this kind of mutations reported till now.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21179066      PMCID: PMC3060314          DOI: 10.1038/ejhg.2010.188

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  54 in total

1.  Predictive identification of exonic splicing enhancers in human genes.

Authors:  William G Fairbrother; Ru-Fang Yeh; Phillip A Sharp; Christopher B Burge
Journal:  Science       Date:  2002-07-11       Impact factor: 47.728

2.  Standardizing mutation nomenclature: why bother?

Authors:  Johan T den Dunnen; Mark H Paalman
Journal:  Hum Mutat       Date:  2003-09       Impact factor: 4.878

3.  Adult-onset glycogen storage disease type II: phenotypic and allelic heterogeneity in German patients.

Authors:  M Vorgerd; B Burwinkel; H Reichmann; J P Malin; M W Kilimann
Journal:  Neurogenetics       Date:  1998-03       Impact factor: 2.660

Review 4.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

Authors:  Nina Raben; Paul Plotz; Barry J Byrne
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

5.  Aberrant splicing at catalytic site as cause of infantile onset glycogen storage disease type II (GSDII): molecular identification of a novel IVS9 (+2GT-->GC) in combination with rare IVS10 (+1GT-->CT).

Authors:  M Stroppiano; G Bonuccelli; F Corsolini; M Filocamo
Journal:  Am J Med Genet       Date:  2001-06-01

Review 6.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.

Authors:  Hannerieke M P van den Hout; Wim Hop; Otto P van Diggelen; Jan A M Smeitink; G Peter A Smit; Bwee-Tien T Poll-The; Henk D Bakker; M Christa B Loonen; Johannis B C de Klerk; Arnold J J Reuser; Ans T van der Ploeg
Journal:  Pediatrics       Date:  2003-08       Impact factor: 7.124

Review 7.  Pompe disease in infants and children.

Authors:  Priya Sunil Kishnani; R Rodney Howell
Journal:  J Pediatr       Date:  2004-05       Impact factor: 4.406

8.  ESEfinder: A web resource to identify exonic splicing enhancers.

Authors:  Luca Cartegni; Jinhua Wang; Zhengwei Zhu; Michael Q Zhang; Adrian R Krainer
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

9.  Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.

Authors:  Monique M P Hermans; Dik van Leenen; Marian A Kroos; Clare E Beesley; Ans T Van Der Ploeg; Hitoshi Sakuraba; Ron Wevers; Wim Kleijer; Helen Michelakakis; Edwin P Kirk; Janice Fletcher; Nils Bosshard; Lina Basel-Vanagaite; Guy Besley; Arnold J J Reuser
Journal:  Hum Mutat       Date:  2004-01       Impact factor: 4.878

10.  A novel approach to describe a U1 snRNA binding site.

Authors:  Marcel Freund; Corinna Asang; Susanne Kammler; Carolin Konermann; Jörg Krummheuer; Marianne Hipp; Imke Meyer; Wolfram Gierling; Stephan Theiss; Thorsten Preuss; Detlev Schindler; Jørgen Kjems; Heiner Schaal
Journal:  Nucleic Acids Res       Date:  2003-12-01       Impact factor: 16.971

View more
  13 in total

Review 1.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

2.  Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.

Authors:  Jean Christophe Théry; Sophie Krieger; Pascaline Gaildrat; Françoise Révillion; Marie-Pierre Buisine; Audrey Killian; Christiane Duponchel; Antoine Rousselin; Dominique Vaur; Jean-Philippe Peyrat; Pascaline Berthet; Thierry Frébourg; Alexandra Martins; Agnès Hardouin; Mario Tosi
Journal:  Eur J Hum Genet       Date:  2011-06-15       Impact factor: 4.246

Review 3.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

4.  c.1437G>A intron 9 substitution on acid α-glucosidase gene associated with classic infantile-onset Pompe disease phenotype.

Authors:  Andrés Morales; Mikaela I Poling; Marco T Páez; Julio Cabrera; Rodger J McCormick
Journal:  BMJ Case Rep       Date:  2015-07-09

5.  Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.

Authors:  Deeksha S Bali; Jennifer L Goldstein; Suhrad Banugaria; Jian Dai; Joanne Mackey; Catherine Rehder; Priya S Kishnani
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

Review 6.  The missing puzzle piece: splicing mutations.

Authors:  Marzena A Lewandowska
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

7.  Phenotypic implications of pathogenic variant types in Pompe disease.

Authors:  Manuel A Viamonte; Stephanie L Filipp; Zara Zaidi; Matthew J Gurka; Barry J Byrne; Peter B Kang
Journal:  J Hum Genet       Date:  2021-05-11       Impact factor: 3.172

8.  Exon first nucleotide mutations in splicing: evaluation of in silico prediction tools.

Authors:  Lucie Grodecká; Pavla Lockerová; Barbora Ravčuková; Emanuele Buratti; Francisco E Baralle; Ladislav Dušek; Tomáš Freiberger
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

Review 9.  Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides.

Authors:  Aurelie Goyenvalle; Christian Leumann; Luis Garcia
Journal:  J Neuromuscul Dis       Date:  2016-05-27

Review 10.  Type 4B hereditary hemochromatosis associated with a novel mutation in the SLC40A1 gene: A case report and a review of the literature.

Authors:  Wei Zhang; Tingxia Lv; Jian Huang; Xiaojuan Ou
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.